Torsades de pointes following clarithromycin treatment

References

• Moss AJ. Long QT syndrome. JAMA 289(16), 2014–2044 (2003).
   Google Scholar
• Kallergis EM, Goudis CA, Simantirakis EN et al. Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review. ScientificWorldJournal 2012, 212178 (2012).
   Google Scholar
• Paulussen AD, Aerssens J. Risk factors for drug-induced long-QT syndrome. Neth. Heart J. 13(2), 47–56 (2005).
   Google Scholar
• Hensey C, Keane D. Clarithromycin induced torsade de pointes. Ir. J. Med. Sci. 177(1), 67–68 (2008).
   Google Scholar
• Gitler B, Berger LS, Buffa SD. Torsades de pointes induced by erythromycin. Chest 105, 368–372 (1994).
   PubMed Web of Science ®Google Scholar
• Volberg WA, Koci BJ, Su W et al. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J. Pharmacol. Exp. Ther. 302(1), 320–327 (2002).
   PubMed Web of Science ®Google Scholar
• Owen RC Jr, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin. Infec. Dis. 43, 1603–1611 (2006).
   Google Scholar
• Brachmann J, Schlerage BJ, Rosenshtraukh LV et al. Bradycardia-dependent triggered activity: relevance to drug-induced multiform ventricular tachycardia. Circulation 68(4), 846–56 (1983).
   Google Scholar
• Yamaguchi S, Kaneko Y, Yamagishi T et al. Clarithromycin-induced torsades de pointes. J. Jpn. Soc. Intern. Med. 92(1), 143–145 (2003).
   Google Scholar
• Wasmer K, Hindricks G, Kottkamp H. Clarithromycin associated syncope as first manifestation of a congenital long QT-syndrome. Intensivmed. Notfallmed. 36(6), 534–540 (1999).
   Google Scholar
• Zeltser D, Justo D, Halkin A et al. Torsade de pointes due to non cardiac drugs: most patients have easily identifiable risk factors. Medicine 82, 282–290 (2003).
   PubMed Web of Science ®Google Scholar
• Sturgill MG, Rapp RP. Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favourable pharmacokinetic and adverse effect profiles. Ann. Pharmacother. 26(9), 1099–1108 (1992).
   PubMed Web of Science ®Google Scholar
• Diaz GMJ, Morillas BP, Andreu RAL et al. EKG changes in a patient with respiratory infection. An. Med. Intern. 22(7), 351–352 (2005).
   Google Scholar
• Kamochi H, Nii T, Eguchi K et al. Clarithromycin associated with torsades de pointes. Jpn. Circ. J. 63(5), 421–422 (1999).
   Google Scholar
• Lee KL, Jim MH, Tang SC et al. QT prolongation and Torsades de Pointes associated with clarithromycin. Am. J. Med. 104(4), 395–396 (1998).
   Google Scholar
• Cetin M, Yilidrimer M, Ozen S et al. Clarithromycin-induced long QT syndrome: a case report. Case Rep. Med. 2012, 634652 (2012).
   Google Scholar
• Jayasena AYA, Herath HMDR., Jayalath TWA et al. Suspected cardiotoxicity of clarithromycin in critically ill patients. Anaesth. Pain Intensive Care 13(1), 28–30 (2009).
   Google Scholar
• Midoneck SR, Etingin OR. Clarithromycin-related toxic effects of digoxin. N. Eng. J. Med. 333, 1505 (1995).
   Google Scholar
• Hancox JC, McPate MJ, El Harchi A et al. The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol. Ther. 119(2), 118–132 (2008).
   PubMed Web of Science ®Google Scholar
• Chiladakis JA, Kalogeropoulos A, Zagkli F et al. Facilitating assessment of QT interval duration during ventricular pacing. Europace 15(6), 907–914 (2013).
   Google Scholar
• Makkar RR, Fromm BS, Steinman RT et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 270(21), 2590–2597 (1993).
   PubMed Web of Science ®Google Scholar
• Vallejo CN, Rodriguez PD, Sanchez HA et al. Ventricular tachycardia and long QT associated with clarithromycin administration in a patient with HIV infection. Rev. Esp. Cardiol. 55(8), 878–881 (2002).
   Google Scholar
• Hayashi Y, Ikeda U, Hashimoto T et al. Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. Pacing Clin. Electrophysiol. 22(4 Pt 1), 672–674 (1999).
   Google Scholar
• Piquette RK. Torsade de pointes induced by cisapride/clarithromycin interaction. Ann. Pharmacother. 33(1), 22–26 (1999).
   PubMedGoogle Scholar
• Choudhury L, Grais IM, Passman RS. Torsades de pointes due to drug interaction between disopyramide and clarithromycin. Heart Dis. 1(4), 206–207 (1999).
   Google Scholar
• Sekkarie MA. Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. Am. J. Kidney Dis. 30(3), 437–439 (1997).
   Google Scholar
• Alesso L, Colombo H, Torre MD et al. Case report: ventricular tachycardia in a patient treated with amiodarone, ciprofloxacin and clarithromycin. Conference: 9th ISoP Annual Meeting ‘From Pharmacovigilance to Risk Management.’ Reims, France. Drug Saf. 32(10), 985 (2009).
   Google Scholar
• Lai D, Brown G, Macdonald I. Clarithromycin-induced prolonged QT syndrome. Can. J. Hosp. Pharm. 49(1), 33–35 (1996).
   Google Scholar
• Mangoni, AA, Kinirons, MT, Swift CG et al. Impact of age on QT interval and QT disperson in healthy subjects: a regression analysis. Age Ageing 32, 326–331 (2003).
   PubMed Web of Science ®Google Scholar
• Germanakis I, Galanakis E, Parthenakis F et al. Clarithromycin treatment and QT prolongation in childhood. Acta Paediatr. 95(12), 1694–1696 (2006).
   Google Scholar
• Trop-Pedersen C, Moller M, Bloch-Thomsen PE et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N. Engl. J. Med. 341(12), 857–865 (1999).
   Google Scholar
• Halkin A, Roth A, Lurie I et al. Pause-dependent torsade de pointes following acute myocardial infarction: a variant of the acquired long QT syndrome. J. Am. Coll. Cardiol. 38(4), 1168–1174 (2001).
   Google Scholar
• Raza Rajani A, Hussain K, Radaideh GA et al. Long QT syndrome in a patient with complete heart block causing Torsades de pointes. Pak. J. Med. Sci. 28(3), 512–515 (2012).
   Google Scholar
• Pinski SL, Equia LE, Trohman RG. What is the minimal pacing rate that prevents Torsades de pointes? insights from patients with permanent pacemakers. Pacing Clin. Electrophysiol. 25(11), 1612–1615 (2002).
   Google Scholar
• Subbiah RN, Gollob MH, Gula LJ et al. Torsades de pointes during complete atrioventricular block: genetic factors and electrocardiogram correlates. Can. J. Cardiol. 26(4), 208–212 (2010).
   Google Scholar
• Yang P, Kanki H, Drolet B et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 105(16), 1943–1948 (2001).
   Google Scholar
• Roden DM. Taking the “Idio” out of “Idiosyncratic”: predicting Torsades de pointes. Pacing Clin. Electrophysiol. 21(5), 1029–1034 (1998).
   PubMed Web of Science ®Google Scholar
• Abbott GW, Sesti F, Splawski I et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97(2), 175–187 (1999).
   PubMed Web of Science ®Google Scholar
• Vieweg WVR, Hancox JC, Hasnain M et al. Clarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reports. Ther. Adv. Infect. Dis. 1(4), 121–138 (2013).
   PubMedGoogle Scholar
• Khan IA. Clinical and therapeutic aspects of congenital and acquired long QT syndrome. Am. J. Med. 112(1), 58–66 (2002).
   PubMedGoogle Scholar
• Banai S, Tzivoni D. Drug therapy for torsade de pointes. J. Cardiovasc. Electrophysiol. 4(2), 206–210 (1993).
   PubMed Web of Science ®Google Scholar
• DiSegni E, Klein HO, David D et al. Overdrive pacing in quinidine syncope and other long QT interval syndromes. Arch. Intern. Med. 140, 1036–1040 (1980).
   Google Scholar
• Monnig G, Kobe J, Loher A et al. Role of implantable cardioverter defibrillator therapy in patient with acquired long QT syndrome: a long-term follow-up. Europace 14(3), 396–401 (2012).
   Google Scholar